by Sean Hughes | Sep 17, 2024 | UPC
The main issue was whether the lis pendens rules in Articles 29–31 of the Brussels I Regulation (Regulation (EU) No 1215/2012, recast) apply to determine the relationship between the German revocation and UPC revocation proceedings. Mala argued these rules should...
by David Eyre | Sep 16, 2024 | US & International
Background For valuable inventions it is relatively typical for a US patent to be expanded into a family of patent rights. Naturally, the value of patents is further enhanced by extra patent term. Patents with expiry dates beyond the normal 20 year period can be...
by Chloe Sullivan | Aug 29, 2024 | EPO
Background Due to methods of treatment of the human or animal body being excluded from patentability in Europe, applicants are required to claim substances or compositions for use in a method of treatment instead. Thus, there is a need for the term “substances or...
by Juliette Boynton | Aug 28, 2024 | UPC
The matter started when Amgen sued various Sanofi companies and Regeneron for patent infringement of their EP3666797 patent. The patent claims an antibody that binds to the catalytic domain of a PCSK9 protein and its use in treating or preventing...
by Sean Hughes | Jul 11, 2024 | EPO
Vegan Cheese Product Claim T 0629/22 concerned European patent no. 3422865 (subject-matter: vegan cheese and preparation thereof). The product claim was distinguished from the prior art according to the type and amount of starch used in the vegan cheese. However, the...
Recent Comments